Sage Journals: Discover world-class research

Retricted access

Research article

First published 2013-9

Improving Oncology Clinical Programs by Use of Innovative Designs and Comparing Them via Simulations

Olga Marchenko, Joel Miller, Tom Parke [...]

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 2020-02

Project Evaluation and Selection with Task Failures

Wenhui Zhao, Nicholas G. Hall, Zhixin Liu

Production and Operations Management

Open access

Research article

First published 2018-3

Assessing the Financial Value of Patient Engagement

Bennett Levitan, Kenneth Getz, Eric L. Eisenstein [...]

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 1994-1

Use of Extrathoracic Negative Pressure Ventilation in Weaning COPD and Kyphoscoliotic Patients from Mechanical Ventilation

C Del Bufalo, L Fasano, CC Quarta [...]

Respiratory Care

Retricted access

Case report

First published 2013-5

Optimizing Drug Development Programs

Zoran Antonijevic, Martin Kimber, David Manner [...]

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 2014-1

Adaptive Design Applied to Identification of the Minimum Effective Dose in Schizophrenia

Tom Parke, Vladimir Dragalin, Ibrahim Turkoz [...]

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 2017-1

Methodological Extensions of Phase 2 Trial Designs Based on Program-Level Considerations

James Bolognese, Jaydeep Bhattacharyya, Chris Assaid [...]

Therapeutic Innovation & Regulatory Science

Search results

Improving Oncology Clinical Programs by Use of Innovative Designs and Comparing Them via Simulations

Project Evaluation and Selection with Task Failures

Assessing the Financial Value of Patient Engagement

Use of Extrathoracic Negative Pressure Ventilation in Weaning COPD and Kyphoscoliotic Patients from Mechanical Ventilation

Optimizing Drug Development Programs

Adaptive Design Applied to Identification of the Minimum Effective Dose in Schizophrenia

Methodological Extensions of Phase 2 Trial Designs Based on Program-Level Considerations